array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2445) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(62) "REGN - Regeneron to Report First Quarter 2024 Financial and..." ["snippet_en"]=> string(142) "TARRYTOWN N.Y. April 01 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) today announced that it will report its first." ["url"]=> string(115) "https://marketwirenews.com/news-releases/regeneron-to-report-first-quarter-2024-financial-and-6813907667533457.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/57ebf7e6-5756-4c2e-b966-e6d933818ef7" ["source"]=> string(18) "marketwirenews.com" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" } } [1]=> array(7) { ["title_en"]=> string(86) "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day" ["snippet_en"]=> string(157) "Shares of Regeneron Pharmaceuticals Inc. slipped 0.69% to $940.48 Tuesday, on what proved to be an all-around dismal trading session for the stock market,..." ["url"]=> string(145) "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-outperforms-competitors-despite-losses-on-the-day-10a2f390-5ce06124e555" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ce0eb208-fffe-4f22-868f-2bef6909c643" ["source"]=> string(15) "marketwatch.com" ["publication_date"]=> string(10) "2024-02-13" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(24) "Stock Research & Ratings" [2]=> string(15) "Market Movement" [3]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(67) "Regeneron Slumps As Its Biggest Moneymaker Flops Amid Roche Rivalry" ["snippet_en"]=> string(75) "Regeneron reported light sales for its eye-disease drug, Eylea, in the U.S." ["url"]=> string(120) "https://www.investors.com/news/technology/regn-stock-slumps-as-us-eylea-sales-disappoint-exel-stock-slammed-on-guidance/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/60024f32-ef75-4bf0-b473-79607fc50f83" ["source"]=> string(13) "investors.com" ["publication_date"]=> string(10) "2024-01-08" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(21) "Financial Performance" } } [3]=> array(7) { ["title_en"]=> string(157) "Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - TipRanks.com" ["snippet_en"]=> string(169) "TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full y..." ["url"]=> string(186) "https://www.tipranks.com/news/press-releases/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-2-2024" ["image_url"]=> NULL ["source"]=> string(12) "tipranks.com" ["publication_date"]=> string(10) "2024-01-05" ["categories"]=> array(3) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(5) "Event" } } [4]=> array(7) { ["title_en"]=> string(60) "2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)" ["snippet_en"]=> string(194) "Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been" ["url"]=> string(125) "https://www.sharewise.com/us/news_articles/2_Healthcare_Stocks_That_Turned_1000_Into_2400_or_More_TheMotleyFool_20240104_1430" ["image_url"]=> string(78) "https://images.businessradar.com/articles/0f9f14fb-fdd6-4bff-8efe-a7899f9dfe2d" ["source"]=> string(13) "sharewise.com" ["publication_date"]=> string(10) "2024-01-04" ["categories"]=> array(4) { [0]=> string(13) "Data Security" [1]=> string(41) "E-commerce and Technological Developments" [2]=> string(10) "Cybercrime" [3]=> string(24) "Quarterly/Annual Figures" } } [5]=> array(7) { ["title_en"]=> string(82) "Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings" ["snippet_en"]=> string(116) "With a price-to-earnings (or "P/E") ratio of 22.9x Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) may be sending..." ["url"]=> string(87) "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-130106668.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a5c2673e-29e5-4263-bca0-a36a50b213b1" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-12-18" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(24) "Stock Research & Ratings" [2]=> string(15) "Market Movement" [3]=> string(24) "Quarterly/Annual Figures" } } [6]=> array(7) { ["title_en"]=> string(103) "Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review By Benzinga" ["snippet_en"]=> string(91) "Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review" ["url"]=> string(145) "https://uk.investing.com/news/stock-market-news/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind--analyst-review-3222136" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-11-03" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(24) "Stock Research & Ratings" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(14) "Product Review" } } [7]=> array(7) { ["title_en"]=> string(45) "Q3 2023 Abcellera Biologics Inc Earnings Call" ["snippet_en"]=> string(45) "Q3 2023 Abcellera Biologics Inc Earnings Call" ["url"]=> string(84) "https://es-us.finanzas.yahoo.com/news/q3-2023-abcellera-biologics-inc-124221549.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/457aa114-bed2-46e0-9a2f-86fad4ea7902" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-11-03" ["categories"]=> array(2) { [0]=> string(14) "Product Launch" [1]=> string(24) "Quarterly/Annual Figures" } } [8]=> array(7) { ["title_en"]=> string(55) "Regeneron's Q3 profits decline, yet surpasses estimates" ["snippet_en"]=> string(55) "Regeneron's Q3 profits decline, yet surpasses estimates" ["url"]=> string(115) "https://www.investing.com/news/stock-market-news/regenerons-q3-profits-decline-yet-surpasses-estimates-93CH-3219562" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-11-02" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(21) "Financial Performance" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(101) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(44) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(32) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(30) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc